Effect of quetiapine-XR on irritable bowel syndrome

@article{Pae2010EffectOQ,
  title={Effect of quetiapine-XR on irritable bowel syndrome},
  author={Chi-Un Pae},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2010},
  volume={34},
  pages={1162-1163}
}
  • C. Pae
  • Published 2010
  • Medicine
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry
I have read with great interest the paper by Dr. Martín-Blanco and colleagues reporting the case of a patient with refractory irritable bowel syndrome (IBS) and depressive disorder whose digestive symptoms improved after add-on therapy of extended-release formulation of quetiapine fumarate (quetiapine-XR) to existing medications (Martin-Blanco et al., in press). As the intricate pathologic mechanism of IBS, the pharmacological treatment options are also complicated and very difficult resulting… Expand

References

SHOWING 1-10 OF 10 REFERENCES
Irritable bowel syndrome in psychiatric perspectives: a comprehensive review
TLDR
From this review, the routine use of SSRIs for IBS treatment cannot be conclusive due to a paucity of RCTs, although a handful ofRCTs suggested a potentially beneficial effect ofSSRIs over placebo. Expand
Quetiapine in the treatment of refractory irritable bowel syndrome A case report
TLDR
The case of a patient with refractory IBS and depressive disorder whose digestive symptoms improved after extended-release formulation of quetiapine fumarate (quetiAPine-XR) was added to the treatment is described. Expand
Immune dysfunction in patients with functional gastrointestinal disorders
  • S. Kindt, L. Van Oudenhove, +5 authors J. Tack
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2009
TLDR
A shift towards a Th2 cytokine profile is present in FGID, while the cellular immunophenotype remains largely unchanged, which could provide new therapeutic strategies for these disorders. Expand
A preclinical and clinical rationale for quetiapine in mood syndromes
TLDR
Emerging evidence indicates that quetiapine's principal, active, human plasma metabolite, N-desalkyl quetuapine, has high affinity for, and is a potent inhibitor of, the noradrenergic transporter, which is a point of commonality with other conventional antidepressant agents. Expand
Autoantibodies in patients with gut motility disorders and enteric neuropathy
TLDR
A small proportion of patients with inflammatory enteric neuropathy have antibodies directed towards neuronal ion channels, which may represent a possible aetiology of severe functional symptoms in these groups of patients. Expand
Neuropathophysiology of functional gastrointestinal disorders.
  • J. Wood
  • Biology, Medicine
  • World journal of gastroenterology
  • 2007
TLDR
Current concepts for the underlying pathophysiology in terms of the physiology of intestinal secretion, motility, nervous control, sensing function, immuno-neural communication and the brain-gut axis are detailed. Expand
The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects
TLDR
The atypical antipsychotics’ strong influence on HPA-function with pronounced ACTH and cortisol lowering is possibly related to the atypicals’ blockade of serotonergic receptors, but blockade of adrenergic or histaminergic receptors may play a role as well. Expand
Paroxetine to Treat Irritable Bowel Syndrome Not Responding to High-Fiber Diet: A Double-Blind, Placebo-Controlled Trial
TLDR
The difference in overall well-being found in the paroxetine/placebo trial is greater than that found in previously published drug/ placebo trials for IBS. Expand
AGA technical review on irritable bowel syndrome.
TLDR
Psychosocial factors, although not part of IBS per se, have an important role in modulating the illness experience and its clinical outcome. Expand
Regulation of Ionotropic Glutamate Receptors in the Rat Brain in Response to the Atypical Antipsychotic Seroquel (Quetiapine Fumarate)
TLDR
The differences between classical and atypical antipsychotics, as well as among the novel agents, might be relevant for specific aspects of their therapeutic activity and could provide valuable information for the role of glutamate in specific symptoms of schizophrenia. Expand